AI assistant
Sending…
TALPHERA, INC. — Director's Dealing 2018
Jan 26, 2018
35181_dirs_2018-01-26_26f4816e-c483-4301-a727-0c4557cacb2b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2018-01-22
Reporting Person: Hamel Lawrence G (Chief Development Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-22 | Stock Option (Right to Buy) | $2 | A | 95000 | Acquired | 2028-01-21 | Common Stock (95000) | Direct |
Footnotes
F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.
F2: Issued pursuant to the 2011 Equity Incentive Plan.
More from TALPHERA, INC.
Interim / Quarterly Report
2026
May 13
Proxy Solicitation & Information Statement
2026
Apr 29
Director's Dealing
2026
Mar 26
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Major Shareholding Notification
2026
Feb 17